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7RESEARCH ARTICLE Open AccessHeterogeneity analysis of Metastasis Associated
in Colon Cancer 1 (MACC1) for survival prognosis
of colorectal cancer patients: a retrospective
cohort study
Viktor H Koelzer1,2, Pia Herrmann3, Inti Zlobec1, Eva Karamitopoulou1,2, Alessandro Lugli1,2 and Ulrike Stein3,4*Abstract
Background: Metastasis of colorectal cancer (CRC) is directly linked to patient survival. We previously identified the
novel gene Metastasis Associated in Colon Cancer 1 (MACC1) in CRC and demonstrated its importance as
metastasis inducer and prognostic biomarker. Here, we investigate the geographic expression pattern of MACC1 in
colorectal adenocarcinoma and tumor buds in correlation with clinicopathological and molecular features for
improvement of survival prognosis.
Methods: We performed geographic MACC1 expression analysis in tumor center, invasive front and tumor buds on
whole tissue sections of 187 well-characterized CRCs by immunohistochemistry. MACC1 expression in each
geographic zone was analyzed with Mismatch repair (MMR)-status, BRAF/KRAS-mutations and CpG-island methylation.
Results: MACC1 was significantly overexpressed in tumor tissue as compared to normal mucosa (p < 0.001). Within
colorectal adenocarcinomas, a significant increase of MACC1 from tumor center to front (p = 0.0012) was detected.
MACC1 was highly overexpressed in 55% tumor budding cells. Independent of geographic location, MACC1 predicted
advanced pT and pN-stages, high grade tumor budding, venous and lymphatic invasion (p < 0.05). High MACC1
expression at the invasive front was decisive for prediction of metastasis (p = 0.0223) and poor survival (p = 0.0217). The
geographic pattern of MACC1 did not correlate with MMR-status, BRAF/KRAS-mutations or CpG-island methylation.
Conclusion: MACC1 is differentially expressed in CRC. At the invasive front, MACC1 expression predicts best aggressive
clinicopathological features, tumor budding, metastasis formation and poor survival outcome.
Keywords: MACC1, Biomarker, Tumor budding, Colorectal cancer, Prognostic factor, MetastasisBackground
Colorectal cancer (CRC) is still one of the most frequent
malignancies in the Western world with more than 1
million new cases every year. The life time risk to suffer
from CRC is about 5% in developed countries [1,2]. Me-
tastasis of primary colorectal tumors is directly linked to
patient survival and accounts for about 90% of patient* Correspondence: ustein@mdc-berlin.de
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unless otherwise stated.deaths. About half of the subjects with CRC can be
cured by surgery and multimodal treatment, but therapy
options are limited particularly for metastasized patients.
This is demonstrated by 5-year-survival rates of higher
than 90% for early stage patients, 65% for patients with
regional lymph node metastases, and less than 10% in
patients with metastatic disease [2]. Synchronous distant
metastases were already observed in about 30% of CRC
patients, and at least a further third will develop meta-
chronous metastases later, despite primary treatment
with curative intention [2]. Therefore, development of dis-
tant metastases is the most crucial and lethal event during
the disease course, critically limiting therapy options.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and molecular markers are not sufficient for prediction
of metastasis, the development of biomarkers for the
early and precise identification of patients at high-risk for
metastasis at early stages of the disease is of utmost
importance.
We identified the novel gene Metastasis Associated in
Colon Cancer 1, MACC1, based on human colon cancer
specimens [3]. In cell culture, MACC1 drives prolifera-
tion, migration, invasion, wound healing and dissemin-
ation and regulates genes transcriptionally important for
metastasis, e.g. the receptor tyrosine kinase MET. It is
crucially involved in fundamental biological processes, e.g.
apoptosis and epithelial-mesenchymal transition (EMT),
via pathways such as the HGF/MET/MACC1 axis. In sev-
eral xenograft mouse models, MACC1 induces tumor
progression and metastasis [3,4].
In CRC patients, MACC1 is a tumor stage-independent
predictor for metastasis and survival, and allows early iden-
tification of high-risk cases [4-6]. Importantly, MACC1
has also been identified as a valuable biomarker in carcin-
omas of the gastrointestinal tract such as gastric [7],
esophagus [8], pancreatic [9] and hepatobiliary [10-12] as
well as in carcinomas of the lung [13-15], ovaries [16],
breast [17,18], upper urothelial tract [19], nasopharynx
[20], malignant glioma [21,22] and osteosarcomas [23].
Remarkably, MACC1 levels consistently correlated with
tumor progression, development of metastasis and patient
survival in this broad range of solid tumor types, making
MACC1 a decisive driver for disease progression (reviewed
in [24]). The predictive value of MACC1 for therapy re-
sponse was demonstrated in rectal, pancreatic, and ad-
vanced hepatocellular cancer [24]. Thus, MACC1 might
be employed as a routine biomarker for diagnosis, disease
prognosis and prediction of therapy response in the
clinic. Tissue- and blood-based diagnostic tests have
already been performed in retrospective and prospective
studies [24].
However, the expression pattern of MACC1 protein
within heterogeneous tumors with respect to refinement
of patient risk assessment has not been addressed. Aim
of this study is therefore to evaluate the geographic ex-
pression pattern of MACC1 protein in the tumor center,
the invasion front and in tumor buds of clinical CRC
samples. In parallel, we determined mismatch repair
(MMR)-status, BRAF/KRAS-mutations and CpG-island
methylation to determine the impact of oncogenic driver
mutations on MACC1 expression. Taken together, we
report for the first time the differential expression of
MACC1 in CRC with increasing levels from tumor cen-
ter to invasion front. MACC1 expression at the invasion
front was identified as the best predictor for aggressive
clinicopathological features, tumor budding, metastasis
formation and poor survival outcome.Methods
Patients and study design
Two hundred and twenty unselected, non-consecutive
CRC patients surgically treated from 2004–2007 at the
Aretaieion University Hospital, University of Athens,
Greece were included in this study [Figure 1]. Clinical
information on patient gender, age at diagnosis, tumor
diameter, tumor location, post-operative therapy and
disease-specific survival time was obtained from patient
records. An experienced gastrointestinal pathologist (EK)
reviewed all histopathological slides according to the
UICC TNM Classification 7th edition. Data on patho-
logical T (pT), N (pN), and M-stage (pM), the presence of
lymphatic invasion (L), venous invasion (V), perineural in-
vasion (Pn), tumor grade (G), histological subtype and
tumor growth pattern was recorded. Tumor budding was
assessed using the 10 high-power fields (10HPF) method
(40×; HPF field area 0.049 mm2) of highest density along
the invasive front [25,26]. For each case, one full tissue
section of invasive adenocarcinoma including the geo-
graphic areas tumor center, invasive front and tumor buds
were selected for analysis of MACC1 expression by immu-
nohistochemistry. Peritumoral normal mucosa was evalu-
ated for MACC1 expression where available (n = 59). 33
cases were excluded based on insufficient material
remaining on the tissue block. Final patient number was
187. Patient characteristics are found in [Table 1]. This
study was designed in accordance with the reporting
recommendations for tumor marker prognostic studies
(REMARK) criteria [27].
Ethics committee approval
The use of patient data has been approved by the Ethics
Committee at the University of Athens, Greece.
Tissue sections and MACC1 immunohistochemistry
Full tissue sections from formalin-fixed, paraffin-embedded
surgical resection specimens were cut at 4 μm. For immu-
nohistochemistry of MACC1, sections were deparaffinized
by successive immersions in xylene (20 minutes), acetone/
Tris 2:1, acetone/Tris 1:2, Tris/NaCl, aqua dest (5 minutes
each). Epitopes were demasked with 10 mM citrate buffer
(pH 6, microwave). After blocking (5% goat serum, 30 mi-
nutes), sections were incubated with the rabbit polyclonal
anti-MACC1 antibody (1:100, Sigma HPA020103) for
three hours at room temperature. Detection was per-
formed using the biotin-based ABC kit (Dako; anti-rabbit
biotin antibody and anti-biotin-streptavidin-HRP) and di-
aminobenzidine (1 minute) as substrate. Counter staining
with Mayer’s haematoxylin was done for 2 minutes.
Negative biological controls were performed using a
matched multi-punch tissue microarray (TMA) of 50
CRC cases including normal mucosa [Figure 2A] and
tumor tissue, negative technical controls were carried out
Figure 1 Study design. 220 CRC patients with full clinicopathological features were entered into the study. Cases were analyzed for BRAF and
KRAS mutations and MMR-protein expression was determined. Tumors of the CpG-Island methylator phenotype were identified using pyrosequencing.
MACC1 protein expression in normal mucosa, tumor center, tumor front and tumor buds was evaluated by immunohistochemistry using full tissue
sections. MACC1 expression in each geographic area of CRC was analyzed with clinicopathological features, patient survival and molecular features.
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file 1: Figure S1].
Evaluation of MACC1
We analyzed MACC1 expression in each geographic
zone (normal mucosa, tumor center, invasive front) of
whole tissue sections in analogy to the Rüschoff criteria
for evaluation of Her2 biomarker expression [28]. Briefly,
MACC1 expression was scored from 0 (absent staining)
to 3 (strong staining). A score of 3 was assigned when a
strong, unequivocally positive cytoplasmic and/or nuclear
staining was observed at low magnification (5×) in a given
geographic area. A score of 2 was assigned when higher
magnification (10×) was needed to recognize MACC1
positivity. When high-power magnification (20×-40×) was
required to recognize MACC1 positivity, a score of 1 was
assigned. For tumor buds, the total number of buds was
counted in one HPF of highest density at the invasive
front and the number and proportion of buds showing
MACC1 positivity was recorded.
KRAS, BRAF and MMR status
BRAF (exon 15, V600E mutations) and KRAS (exon 2,
codon 12 and 13) mutations were analyzed using pyrose-
quencing as previously described [29]. For identification
of tumors with high-level CpG island methylation (CpG
island methylator phenotype, CIMP), PCR analysis ofCpG-loci of six genes (SOCS1, NEUROG1, MLH1,
CRABP1A, CDKN2A, RUNX3) was carried out by pyro-
sequencing as recently reported [29].
Mismatch-repair (MMR) protein expression was deter-
mined by immunohistochemistry for MLH1, MSH2,
MSH6, and PMS2 using a multi-punch tissue microarray
containing an average of four tumor cores per case.
Staining was carried out as previously described. MMR-
protein expression was scored as positive when staining
for all MMR-proteins was observed.
Statistical analysis
MACC1 positive cases were defined as MACC1 scores
1–3 by immunohistochemistry, negative cases were de-
fined as score 0. Differences in MACC1 expression by
geographic area and tissue type were analyzed using the
Kruskal-Wallis test. The correlation of MACC1 expres-
sion with clinicopathological and molecular features was
evaluated using the Chi-Square, or Fisher’s Exact test as
appropriate. Survival time analysis was performed using
Kaplan-Meier curves and tested using the log-rank test
in univariate analysis. Multivariate analysis for the prog-
nostic effect of MACC1 expression at the tumor front
and the potential confounders pT, pN, pM and adjuvant
therapy was performed using a Cox regression model
after verification of the proportional hazards assumption.
Adjustment for multiple hypothesis testing was not
Table 1 Patient characteristics and association of MACC1
expression in the tumor center with clinicopathological
data
Characteristics Total
(n = 187)
MACC1 tumor center N (%);
(n = 187)
P-value
Low
(Score 0)
High
(Score 1–3)
N = 78
(41.7%)
N = 109
(58.3%)
Age (yrs.)
Mean (min, max) 68.6 (35–93) 69.2 (36–93) 68.1 (35–91) 0.1732
Tumor size (cm)
Mean (min, max) 4.5 (1.2–12) 4.8 (2–12) 4.3 (1.2–8) 0.5723
Gender
Male 88 (47.3) 35 (44.9) 53 (49.1) 0.5711
Female 98 (52.7) 43 (55.1) 55 (50.9)
Histological subtype
Non-mucinous 167 (89.3) 70 (89.7) 97 (89.0) 0.8695
Mucinous 20 (10.7) 8 (10.3) 12 (11.0)
Tumor grade
G1-2 120 (64.2) 55 (70.5) 65 (59.6) 0.126
G3 67 (35.8) 23 (29.5) 44 (40.4)
Tumor location
Left 113 (60.7) 42 (53.9) 71 (65.7) 0.2027
Rectum 21 (11.3) 9 (11.5) 12 (11.1)
Right 52 (28.0) 27 (34.6) 25 (23.2)
pT
pT1 + pT2 47 (25.1) 26 (33.3) 21 (19.3) 0.0288
pT3 + pT4 140 (74.9) 52 (66.7) 88 (80.7)
pN
pN0 97 (51.9) 51 (65.4) 46 (42.2) 0.0018
pN1-2 90 (48.1) 27 (34.6) 63 (57.8)
pM
pM0 167 (89.8) 73 (93.6) 94 (87.0) 0.1454
pM1 19 (10.2) 5 (6.4) 14 (13.0)
TNM stage
Stage I 40 (21.5) 26 (33.3) 14 (13.0) 0.0023
Stage II 53 (28.5) 24 (30.8) 29 (26.9)
Stage III 74 (39.8) 23 (29.5) 51 (47.2)
Stage IV 19 (10.2) 5 (6.4) 14 (13.0)
Tumor budding
Low-grade 101 (54.0) 54 (69.2) 47 (43.1) 0.0004
High-grade 86 (46.0) 24 (30.8) 62 (56.9)
Venous invasion
Present 32 (17.1) 8 (10.3) 24 (22.0) 0.0352
Absent 155 (82.9) 70 (89.7) 85 (78.0)
Table 1 Patient characteristics and association of MACC1
expression in the tumor center with clinicopathological
data (Continued)
Lymphatic invasion
Present 74 (39.6) 24 (30.8) 50 (45.9) 0.0373
Absent 113 (60.4) 54 (69.2) 59 (54.1)
Therapy
Untreated 66 (35.3) 39 (50.0) 27 (24.8) 0.0004
Treated 121 (64.7) 39 (50.0) 82 (75.2)
MMR status
Proficient 170 (91.4) 71 (91.0) 99 (91.7) 0.8777
Deficient 16 (8.6) 7 (9.0) 9 (8.3)
KRAS status
Wild-type 124 (67.0) 54 (70.1) 70 (64.8) 0.4484
Mutation 61 (33.0) 23 (29.9) 38 (35.2)
BRAF status
Wild-type 165 (91.2) 69 (92.0) 96 (90.6) 0.7378
Mutation 16 (8.8) 6 (8.0) 10 (9.4)
CIMP status
Negative/Low 90 (87.4) 40 (90.9) 50 (84.8) 0.3887
High 13 (12.6) 4 (9.1) 9 (15.3)
Survival rate
Median 60 (50-ne) Not reached 58 (43-ne) 0.2585
ne = survival endpoint not reached.
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cally significant. Analyses were performed using SAS
(V9.2, The SAS Institute, Cary, NC).
Results
Geographic analysis of MACC1 expression
MACC1 was significantly over-expressed in tumor tissue
as compared to normal mucosa (p < 0.001) [Figure 2A].
In tumor tissue, a gradient of MACC1 expression from
the tumor center to the invasive front was identified
(p = 0.0012) [Figure 2B]. In tumor buds, a strong cyto-
plasmic expression was observed: 55% of the dissociated
single cells or small clusters of up to five cells identified
at the invasive front demonstrated MACC1 expression
[Figure 2B]. No MACC1 expression was observed in the
tumor stroma.
MACC1 expression in the tumor center
In the tumor center, MACC1 expression (score 1–3) was
observed in 58.3% of cases. Patients with strong MACC1
expression in the tumor center frequently presented with
locally advanced pT3/4 tumors (p = 0.0288) as compared
to MACC1 negative cases [Table 1]. In fact, 80% of
MACC1 positive tumors showed infiltration into the
Figure 2 MACC1 protein expression analysis in CRC. A: MACC1 expression in normal mucosa (1), tumor center (2), tumor front (3) and tumor
buds (4; arrows) was evaluated by immunohistochemistry. B: Four representative cases of colorectal adenocarcinoma showing a significant
increase of MACC1 expression from the tumor center towards the invasive front and MACC1 over-expressing tumor budding cells.
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tivity in the tumor center further predicted aggressive
tumor growth with presence of lymphatic invasion (p =
0.0373), venous invasion (p = 0.0352) and frequent me-
tastasis to loco regional lymph nodes (p = 0.0018). Fur-
ther, MACC1 expression in the tumor center was highly
correlated with presence of high-grade tumor budding.
However, no impact of MACC1 expression in the tumorcenter on the frequency of distant metastasis or patient
survival was observed.
MACC1 expression at the invasive front
At the tumor front, MACC1 expression was observed in
72.2% of cases. MACC1 staining at the tumor front was
seen in aggressive tumors with more advanced pT-stage
(p = 0.0005), presence of lymphatic (p = 0.002) and venous
Koelzer et al. BMC Cancer  (2015) 15:160 Page 6 of 11(p = 0.0125) invasion as well as frequent nodal metastasis
(p = 0.0001) [Table 2]. MACC1 expression at the tumor
front was strongly predictive for the formation of distant
metastasis (p = 0.0223). In fact, 18 of 19 patients with dis-
tant metastasis were correctly identified based on marker
expression in this geographic area, indicating that MACC1
expression at the tumor host interface may be particularly
important for tumor spread to distant organs. In consist-
ence with this, strong MACC1 expression at the invasive
front correlated with a high grade tumor budding pheno-
type (p = 0.0006). MACC1 positivity at the invasive front
predicted poor overall survival outcome (p = 0.0217) in
univariate analysis [Figure 3], however the prognostic
impact of marker expression was not independent of
T-stage, N-stage and adjuvant therapy as identified in
multivariable analysis (p = 0.7827) [Table 3].
MACC1 expression in tumor buds
MACC1 expression was observed in 55% of tumor buds.
In tumor buds, MACC1 expression correlated with ag-
gressive disease biology. A higher proportion of MACC1
positive tumor buds was detected in patients with more
advanced T-stage (p < 0.0001), higher overall TNM-stage
(p = 0.0004) and presence of nodal metastasis (p = 0.0453)
[Table 2]. No impact of MACC1 expression in tumor buds
on survival was observed.
Geographic expression patterns of MACC1 in a molecular
pathology context
KRAS mutations were identified in 32.6% of patients
(n = 61) by pyrosequencing, while activating BRAF (V600)
mutations were found in 8.5% of patients (n = 16). 8.5% of
patients showed loss of MMR-protein expression by im-
munohistochemistry, while 7% (n = 13) of cases were clas-
sified as CIMP-high. No impact of molecular features on
MACC1 protein expression was observed independent of
the geographic area analyzed.
Discussion
In the current study we perform a geographic analysis of
MACC1 expression in CRC with a particular focus on
EMT-like cancer cells in the tumor microenvironment,
also called tumor buds. As molecular features of CRC
impact prognosis, we correlate MACC1 protein expres-
sion with MMR-status, BRAF- and KRAS-mutation as
well as CpG-island methylation.
We demonstrate that MACC1 is variably expressed in
normal mucosa, tumor center, invasive front and tumor
buds. CRC is a highly heterogeneous disease character-
ized by marked genetic, spatial and temporal dynamics
[31]. Tumor heterogeneity is present even in early inva-
sive disease and may affect the reproducibility of bio-
marker assessment [32]. In a novel geographic approach
towards immunohistochemical MACC1 expression analysison full tissue sections, we identify a progressive increase
of MACC1 positivity from the tumor center towards the
invasive front with frequent overexpression in tumor bud-
ding cells. MACC1 gene function has been implicated in
disease progression of CRC through activation of the
MET- and beta-catenin (CTNNB1) pathways [3,33]. Acti-
vation of EMT in the process of invasion is a central step
towards the seeding of metastasis [34-36]. Importantly,
MACC1 overexpression at the invasive front was signifi-
cantly associated with presence of distant metastasis and
was a strong prognostic indicator. As death from CRC is
predominantly determined by metastatic dissemination,
the prognostic impact of MACC1 in this geographic area
further corroborates the exceptional importance of the
tumor microenvironment for determining prognosis [37].
Tumor budding is officially recognized by the Union
for International Cancer Control (UICC) as an inde-
pendent additional prognostic indicator in CRC [38]. A
high grade tumor budding phenotype is consistently as-
sociated with aggressive clinicopathological features,
lymph node and distant metastasis [36]. It is thought
that tumor budding at the tumor invasive front is a histo-
morphological hallmark of EMT. Tumor buds overexpress
protein markers associated with tumor cell migration and
invasion such as matrix metallopeptidase 2 (MMP2),
MMP9 and cathepsinB (CTSB) [36]. Interestingly, MMP9
was previously described as being regulated by MACC1 in
hepatocellular carcinoma and gastric cancer cell lines
[39,40]. Further, activation of WNT-signaling and loss of
E-Cadherin (CDH1) contributes to dissociative growth of
tumor budding cells and loss of an epithelial phenotype.
The expression of proteins such as Raf-kinase inhibitor
protein (RKIP) and neurotrophic tropomyosine kinase re-
ceptor type 2 (NTRK2) contribute to the resistance to
apoptosis and anoikis [41,42]. Interestingly, MACC1 over-
expression in any geographic region of CRC was signifi-
cantly associated with high grade tumor budding at the
invasive front and aggressive histopathological features in-
cluding more advanced pT and pN-stages, venous and
lymphatic invasion. In consistence with recently published
literature, this suggests that active MET signaling contrib-
utes to dissociative tumor growth, tumor progression and
invasion [43]. MACC1 overexpression in tumor budding
cells themselves provides further evidence of their bio-
logical aggressiveness and likens these cells to EMT-like
cancer cells [43]. As MACC1 has been suggested as a po-
tential therapeutic target, overexpression on EMT-like
cancer cells may represent an attractive option to manipu-
late cancer initiating cells at the tumor host interface in
the process of invasion [44].
Biomarkers with predictive value for metastatic disease
relapse have the potential to aid clinical management of
CRC patients as additional prognostic indicators. The
current approach towards active surveillance of CRC
Table 2 Association of MACC1 expression in the tumor front and tumor buds with clinicopathological data
Characteristics MACC1 tumor front N (%); (n = 187) P-value MACC1 tumor buds N (%); (n = 187) P-value
Low (Score 0) High (Score 1–3) Low (<median) High (>median)
Age (yrs.)
Mean (min, max) 69.9 (38–88) 68.1 (35–93) 0.1141 70.1 (36–89) 67.6 (41–91) 0.0408
Tumor size (cm)
Mean (min, max) 5.0 (2–12) 4.4 (1.2–8.0) 0.4457 4.6 (2–12) 4.5 (1.2–8) 0.7134
Gender
Male 18 (35.3) 70 (51.9) 0.0436 23 (46.0) 32 (45.1) 0.9195
Female 33 (64.7) 65 (48.2) 27 (54.0) 39 (54.9)
Histological subtype
Non-mucinous 46 (90.2) 121 (89.0) 0.8092 45 (90.0) 61 (85.9) 0.502
Mucinous 5 (9.8) 15 (11.0) 5 (10.0) 10 (14.1)
Tumor grade
G1-2 36 (70.6) 84 (61.8) 0.2624 30 (60.0) 35 (49.3) 0.2449
G3 15 (29.4) 52 (38.2) 20 (40.0) 36 (50.7)
Tumor location
Left 27 (52.9) 86 (63.7) 0.3547 30 (60.0) 43 (61.4) 0.7867
Rectum 6 (11.8) 15 (11.1) 7 (14.0) 7 (10.0)
Right 18 (35.3) 34 (25.2) 13 (26.0) 20 (28.6)
pT
pT1 + pT2 22 (43.1) 25 (18.4) 0.0005 15 (30.0) 3 (4.2) <0.0001
pT3 + pT4 29 (56.9) 111 (81.6) 35 (70.0) 68 (95.8)
pN
pN0 38 (74.5) 59 (43.4) 0.0001 26 (52.0) 24 (33.8) 0.0453
pN1-2 13 (25.5) 77 (56.6) 24 (48.0) 47 (66.2)
pM
pM0 50 (98.0) 117 (86.7) 0.0223 47 (94.0) 60 (85.7) 0.1499
pM1 1 (2.0) 18 (13.3) 3 (6.0) 10 (14.3)
TNM stage
Stage I 22 (43.1) 18 (13.3) <0.0001 13 (26.0) 1 (1.4) 0.0004
Stage II 15 (29.4) 38 (282.) 12 (24.0) 20 (28.6)
Stage III 13 (25.5) 61 (45.2) 22 (44.0) 39 (55.7)
Stage IV 1 (2.0) 18 (13.3) 3 (6.0) 10 (14.3)
Tumor budding
Low-grade 38 (74.5) 63 (46.3) 0.0006 28 (56.0) 20 (28.2) 0.0021
High-grade 13 (25.5) 73 (53.7) 22 (44.0) 51 (71.8)
Venous invasion
Present 3 (5.9) 29 (21.3) 0.0125 7 (14.0) 19 (26.8) 0.0924
Absent 48 (94.1) 107 (78.7) 43 (86.0) 52 (73.2)
Lymphatic invasion
Present 11 (21.6) 63 (46.3) 0.002 24 (48.0) 38 (53.5) 0.5496
Absent 40 (78.4) 73 (53.7) 26 (52.0) 33 (46.5)
Therapy
Untreated 29 (56.9) 37 (27.2) 0.0002 24 (48.0) 9 (12.7) <0.0001
Treated 22 (43.1) 99 (72.8) 26 (52.0) 62 (87.3)
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Table 2 Association of MACC1 expression in the tumor front and tumor buds with clinicopathological data (Continued)
MMR status
Proficient 44 (86.3) 126 (93.3) 0.1256 46 (92.0) 63 (90.0) 0.7607
Deficient 7 (13.7) 9 (6.7) 4 (8.0) 7 (10.0)
KRAS status
Wild-type 32 (64.0) 92 (68.2) 0.594 33 (66.0) 46 (65.7) 0.974
Mutation 18 (36.0) 43 (31.9) 17 (34.0) 24 (34.3)
BRAF status
Wild-type 45 (90.0) 120 (91.6) 0.772 44 (89.8) 60 (89.6) 0.966
Mutation 5 (10.0) 11 (8.4) 5 (10.2) 7 (10.5)
CIMP status
Negative/Low 27 (90.0) 63 (86.3) 0.7514 21 (84.0) 36 (83.7) 1.0
High 3 (10.0) 10 (13.7) 4 (16.0) 7 (16.3)
Survival rate
Median Not reached 58 (43-ne) 0.0217 53.0 (43–61) 55.0 (36-ne) 0.839
ne = survival endpoint not reached.
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cinoembryonic antigen, but suffers from suboptimal sen-
sitivity and specificity [45]. As metastatic relapse is a
decisive event that determines prognosis of the CRC pa-
tient, early identification of high risk patients is an
important goal for biomarker development. Several bio-
markers have recently been highlighted to guide the
identification of patients at risk of metastatic relapse. Ex-
amples include expression of RKIP in the primary tumor
[41] and serum biomarkers such as microRNA-200c
[46]. Based on the variety of detection methods, possibil-
ities for assessment in tumor tissue and plasma and in-
clusion in early clinical trials, MACC1 is a promising
candidate in the growing list of potentially valuableFigure 3 Prognostic effects of MACC1 expression at the invasive fron
adverse prognostic indicator (p = 0.0217) in univariate survival analysis.biomarkers to aid the identification of high risk CRC pa-
tients [6,24].
Molecular markers such as KRAS- and BRAF-mutations
contribute predictive information for response to EGFR-
inhibitors, but their value for identification of patients at
high risk of metastatic relapse independent of disease
stage is limited [47]. Interestingly, MACC1 expression was
found to be independent of oncogenic driver mutations
including activating KRAS-, BRAF- mutations, micro-
satellite instability and CIMP. This suggests that the asso-
ciation of MACC1 overexpression with presence of
metastatic disease may be independent of the genetic fea-
tures of CRC. MACC1 may therefore represent a comple-
mentary biomarker to KRAS- and BRAF- gene mutationt of CRC. MACC1 overexpression at the tumor front is a significant
Table 3 Multivariable Cox-regression analysis of MACC1
expression at the tumor front TNM-stage and adjuvant
therapy
Parameter HR (95%CI) P-value
MACC1
Low (Score 0) 1.0 0.7827
High (Score 1–3) 1.1 (0.56-2.16)
pT
pT1-2 1.0 0.3425
pT3-4 1.52 (0.64-3.57)
pN
pN0 1.0 0.0003
pN1-2 3.48 (1.77-6.85)
pM
pM0 1.0 <0.0001
pM1 4.12 (2.2-7.68)
Adjuvant therapy
None 1.0 0.3284
Treated 0.74 (0.4-1.36)
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of metastatic relapse. However, based on the relatively
small number of cases identified with KRAS-, BRAF-
mutations, CIMP or MMR-deficiency, this data cannot
exclude an association between MACC1 and the mo-
lecular markers under study and requires independent
validation.
This investigation has several strengths. The study is
designed based on a hypothesis driven approach in full
accordance with the REMARK guidelines for tumor
marker prognostic studies [27]. Analyses are based on a
very well characterized cohort of 187 CRC patients with
full clinicopathological data, follow-up and therapy in-
formation. Marker analysis on full tissue sections ac-
counts for tumor heterogeneity and allows expression
analysis in tumor buds at the tumor-host interface.
Weaknesses include the relatively small patient number
included in the analysis of molecular pathology features
with MACC1 expression. Further, marker cut-off levels
may be influenced by the analysis methods and specific
characteristics of the cohort under study. Consequently
we recommend validation of the geographic expression
pattern of MACC1 as a biomarker using independent
patient cohorts.
Conclusions
This study further advances the development of MACC1
as a predictive biomarker. By geographic protein expres-
sion analysis, we illustrate that MACC1 is differentially
expressed in normal mucosa, tumor center and at theinvasive front of colorectal cancer. Marker positivity is
frequently seen in tumor buds and identifies cancer cells
with particularly aggressive behavior. At the invasive
front, MACC1 expression best predicts aggressive clini-
copathological features, tumor budding, and metastasis
formation. MACC1 biomarker expression was not influ-
enced by MMR-status, BRAF or KRAS-mutations or
CpG-island methylation. Based on meaningful functional
data and strong potential for translational application,
MACC1 has to be classified as a promising biomarker
for validation in prospective studies.
Additional file
Additional file 1: Figure S1. Technical controls. No immune reactivity
was observed in technical controls of normal mucosa (A), tumor center
(B), tumor front (C) and tumor buds (D; arrows).
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